Business
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world’s premier virtual rheumatology experience, will take place online November 3 - 10.\n\nTitle: Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study\nFirst Author: Dr. Kenneth Kalunian, Professor, Medicine, UCSD School of Medicine\nSession Title: SLE – Treatment Poster (1732–1772)\nSession Type: Poster Session D\nDate and Time: 8:30 am – 10:30 am ET, Tuesday, November 9, 2021\nAbstract Number: 1750\n\nThe abstract highlights itolizumab (subcutaneous delivery) safety and tolerability, as well as PK/PD data from patients with active or inactive systemic lupus erythematosus (SLE) in the TYPE A portion of the EQUALISE study, supporting continued evaluation of itolizumab in SLE, lupus nephritis (LN) and other chronic autoimmune diseases. The ongoing Part B portion of the study will assess the safety and efficacy of itolizumab in patients with active proliferative LN.\n\nTitle: Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients\nFirst Author: Dalena Chu, Senior Research Associate, Equillium, Inc.\nSession Title: SLE – Treatment Poster (1732–1772)\nSession Type: Poster Session D\nDate and Time: 8:30 am – 10:30 am ET, Tuesday, November 9, 2021\nAbstract Number: 1766\n\nThe abstract outlines pharmacodynamic data from the Type A portion of the EQUALISE study in which subcutaneous delivery of itolizumab induces dose-dependent loss of cell surface CD6 on T cells (with maximal loss occurring at 1.6 mg/kg), leading to inhibition of T effector cell activity.\n\nTitle: Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis\nFirst Author: Dalena Chu, Senior Research Associate, Equillium, Inc.\nSession Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\nSession Type: Poster Session A\nDate and Time: 8:30 am – 10:30 am ET, Saturday, November 6, 2021\nAbstract Number: 035...